First drug to delay onset of type 1 diabetes made available on NHS

• Teplizumab, an immunotherapy, is now available on the NHS as the first disease-modifying treatment to delay type 1 diabetes onset by approximately three years
• The drug targets the underlying autoimmune process rather than managing symptoms, offering a preventive approach for at-risk individuals before insulin dependence develops
• This represents a significant shift in type 1 diabetes management, moving from post-diagnosis treatment to pre-symptomatic intervention in both paediatric and adult populations

The immunotherpay can give children and adults three extra years before they need to use insulin.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.